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Abstract
Alzheimer’s disease and vascular dementia are two major diseases associated with dementia, which is common
among the elderly. While the etiology of dementia is multi-factorial and complex, neurodegeneration may be the
major cause of these two diseases. Effective drugs for treating dementia are still to be discovered. Current western
pharmacological approaches against neurodegeneration in dementia develop symptom-relieving and disease-
modifying drugs. Current integrative and holistic approaches of Chinese medicine to discovering drugs for
neurodegeneration in dementia include (1) single molecules from the herbs, (2) standardized extracts from a single
herb, and (3) herbal formula with definite composition. This article not only reviews the concept of dementia in
western medicine and Chinese medicine but also evaluates the advantages and disadvantages of these
approaches.
Introduction
Alzheimer’s disease (AD) and vascular dementia (VaD)
are the major forms of dementia. In addition, in the
postmortem brains of the late stage of Parkinson’s dis-
ease/Lewy body disease also find pathological hallmarks
of AD [1]. Senile dementia is the progressive decline of
memory and some related cognitive functions in the
elderly. The global dementia population is predicted to
reach 81.1 million by 2040 [2]. In 2010, the estimated
prevalence of senile dementia in China is 6.0 to 7.0 mil-
lion, accounting for about one-sixth of the global preva-
lence; the prevalence is expected to increase to 22.5
million by 2040, accounting for one-fourth of the global
prevalence by that time [3]. The rapid increase in the
number of dementia patients urgently demands effective
prevention and treatment. Current approaches to
dementia-related neurodegenerative diseases still highly
rely on relieving symptoms. As some Chinese medicinal
herbs have been used in treating dementia, many
researchers are now turning to Chinese medicine for
identifying potential neuroprotective agents or disease-
modifying agent. This article reviews the strategy in the
research of Chinese medicine in dementia related-neu-
rodegenerative diseases.
Dementia and medical sciences
AD is clinically characterized by the progressive loss of
memory, cognitive functions and behavioral changes.
The pathogenesis of AD has been widely studied [4,5],
in which beta-amyloid (Ab) peptide and hyperpho-
sphorylated tau protein as components of extracellular
senile plaques and intracellular neurofibrillary tangles,
respectively, are believed to be the targets for developing
disease-modifying drugs. Current AD treatments are all
symptom-relieving agents and heavily rely on the use of
acetylcholinesterase (AChE) inhibitors (donepezil, rivas-
tigmine and galantamine). AChE inhibitors slow down
the degradation of the neurotransmitter acetylcholine,
thereby increasing its bioavailability. Another approved
AD treatment aims to reduce glutamate excitotoxicity.
Memantine, the only approved drug in this category,
acts as a non-competitive N-methyl-D-aspartate
(NMDA) receptor antagonist to reduce glutamate-
mediated neurotoxicity [6].
Development and progression of VaD are associated
with a number of risk factors, many of which are related
to the pathogenesis of atherosclerosis [7]. Stroke is also a
critical factor for VaD; it was reported that 79.5% of VaD
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patients had a history of stroke [8]. As there is no cure
for VaD, management of VaD emphasizes on the preven-
tion of new stroke and control of vascular risk factors.
Dementia and Chinese medicine
According to Chinese medicine theory, there is no dis-
tinction between AD and VaD. Dementia is caused by
(1) deficiency of vital energy of the Kidney (Shen), Mar-
row (Sui), Heart (Xin) and Spleen (Pi) and (2) stagnation
of Blood (Xie) and/or Phlegm (Tan). Thus, herbs used
for dementia are not specific for the nervous system but
tend to be multi-functional [9].
Standardization of dementia subtype classification and
research guidelines
Guideline for Chinese Medicine Diagnosis, Classification
and Clinical Research of Senile Dementia was published
in 1990. The guideline classified dementia into six sub-
types according to the CM theory: (1) the Bone Marrow
(Gusui) deficiency syndrome, (2) the Liver (Gan) and
Kidney (Shen) Yin deficiency syndrome, (3) the Spleen
(Pi) and Kidney (Shen) Yang deficiency syndrome, (4)
the Qi stagnation and Blood (Xie) stasis syndrome, (5)
the Phlegm Turbid (Tan Zhuo) blocking Orifice (Qing
Qiao) syndrome, and (6) the Heart (Xin) and Liver Fire
(Gan Huo) syndrome [10]. Since then, clinical studies
on dementia in China have been based on this guideline
[11]. More recently, the Guideline Principles for Clinical
Research on New Chinese Medicine (trial version) [3]
provides more detailed description on the diagnostic cri-
teria and describes the severity of disease subtypes
quantitatively. The Mini-Mental State Examination
(MMSE) score has also been introduced as the main
reference index [3]. Criteria for the Diagnosis, Differen-
tiation of Syndrome and Evaluation of Efficacy of Vascu-
lar Dementia for Research Studies were published on
2002, emphasizing that the diagnosis of VaD must meet
the NINDS-AIREN criteria (developed by the National
Institute of Neurological Disorders and Stroke (NINDS)
and the Association Internationale pour la Recherche et
l’Enseignement en Neurosciences (AIREN)) and that the
differentiation of syndromes in Chinese medicine should
be based on the scale for the differentiation of syn-
dromes of vascular dementia (SDSVD) published in
2000 [12]. It classifies VaD in 7 syndromes according to
CM diagnosis: (1) the Kidney Essence (Shen Jing) defi-
ciency syndrome, (2) the Phlegm Turbid (Tan Zhuo)
blocking Orifice (Qing Qiao) syndrome, (3) the vessels
obstructed by Blood Stasis (Xie Yu) syndrome, (4) the
brain aggressed by Liver’s (Gan) Yang syndrome, (5) the
Heat (Re) and Toxin (Du) accumulation syndrome, (6)
the Qi and Blood (Xie) deficiency syndrome, and (7) the
constipation and toxin in intestines syndrome. SDSVD
employs a detailed scoring system to assist syndrome
differentiation and diagnosis [13].
Chinese medicine approaches based on the etiology of
dementia
Chinese medicine theory considers dementia to be a
more holistic and integrated approach, rather than a
problem in just one organ. Dementia is complex and
may involve multiple causes. During progression of
dementia, the significant of different pathological factors
may also change. In Chinese medicine, it is believed that
the disease is highly correlated to the abnormal func-
tions of other organs including the Kidney (Shen), Liver
(Gan), Heart (Xin) and Spleen (Pi), although the patho-
logical site of dementia is in the brain. For example,
dementia patients who initially have Kidney (Shen) defi-
ciency may also develop stagnation of Blood (Xie) and
Phlegm (Tan) leading to dementia. All these clinical
experiences, stagnation of blood and kidney deficiency,
become two important concepts in Chinese medicine to
explain the origin of sickness leading to dementia
[14-16].
Chinese medicine studies on the prevalence and distribution
of dementia subtypes
In order to integrate Chinese medicine diagnosis, some
researchers investigated the prevalence and distribution
of dementia subtypes. Wang et al. found that deficiency
of Qi, Blood (Xie), Essence (Jing) was present in most
dementia cases and that Heart (Xin) and Kidney (Shen)
were most commonly afflicted by the condition [17].
Yang et al. found that stagnation of Blood (Xie) and
Phlegm (Tan) were frequently present in moderate and
severe AD cases [18]. While these data are not diagnos-
tic criteria, they provide important information for the
prevention of pathological progression in dementia.
Chinese medicine research on treatment of dementia
Nowadays, the development of Chinese herbal medicine
mainly adopted three approaches, which include the sin-
gle molecule approach, standardized extracted approach
and fixed herbal formula approach. In the following sec-
tions, we will discuss the recent development of each
approach. It is beyond the scope of our report to review
the pharmacological effects of all medicinal herbs for
dementia treatment in detail. In fact, our aim is to use
several representative examples to illustrate the advan-
tages and disadvantages of each approach.
Single molecules from a single herb
Huperzine A Huperzine A is an alkaloid isolated from
Huperzia serrata (Qiancengta) which is documented in
Chinese medicine literature as an anti-inflammatory
herb for relieving pain and alleviating swelling after
trauma. According to the Chinese medicine theory,
Huperzia serrata helps removing Heat (Re) and has
detoxification effects. Huperzine A is widely used in
China to treat AD. Clinical trials demonstrated that
huperzine A significantly improved cognitive functions
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in AD patients [19] and its potential therapeutic effects
for VaD [20]. While evidence for the use of huperzine A
to treat AD was insufficient, a recent Cochrane systema-
tic review reported no obvious adverse effects in AD
patients treated with huperzine A [21].
The anti-AChE activity of huperzine A is the basis for
its use to treat dementia patients [22]. Animal studies
found that huperzine A was comparable to donepezil and
rivastigmine in terms of anti-AChE activity [23]. In vivo
studies showed that huperzine A affected amyloid pre-
cursor protein processing to reduce the formation of Ab
peptides [24]. Other studies also showed that huperzine
A attenuated apoptosis in neurons treated with Ab pep-
tides [25]; and huperzine A elicited anti-oxidative effects
which allowed it to protect neurons against hydrogen
peroxide and Ab-induced oxidative damages [26,27].
Huperzine A was found to improve mitochondrial func-
tions in neurons and reduce the level of reactive oxygen
species in neurons exposed to Ab peptides [28].
Pros and cons of the single molecule approach Huper-
zine A is a chemical drug derived from Chinese medi-
cine as a chemical library [29]. The discovery of
huperzine A as an anti-AChE inhibitor was based on
the observation that the administration of Huperzia ser-
rata extract induced cholinergic stimulation in schizo-
phrenic patients [30]. As the quality and bioavailability
of a herb can be affected by the cultivation environment
and harvesting season [31], single molecule approach
eliminates or minimizes this variation.
However, this approach may also generate problems.
Extraction of active ingredients is often not a simple
task. Interactions of ingredients during preparation pro-
cedure are essential to the therapy. Moreover, evidence
shows that single component extracted from plants is
less potent than crude extract [32]. Researchers often do
not use any Chinese medicine theory as the basis for
their investigation when studying these compounds.
Therefore, some Chinese medicine experts are skeptical
about the approach [33].
Standardized extracts from a single herb
Authentication of herbs Historically, herbs grown in a
particular habitat are considered Daodi (genuine) [34].
Today, the good agricultural practice (GAP) promoted
in China ensures the quality and consistency of a parti-
cular herb [35]. A herbal extract is considered ‘standar-
dized’ if (1) the raw material (herb) is grown and
collected according to the GAP; (2) the extraction fol-
lows a well-defined procedure; and (3) the chemical pro-
files are consistent among batches of extracts.
EGb761 EGb761 is a standardized herbal extract from
the dried leafs of Ginkgo biloba, containing approxi-
mately 24% flavone glycosides (quercetin, kaempferol
and isorhamnetin) and 6% terpene lactones (ginkgolides
A, B, C, J and bilobalide) [36]. Dried fruit of Ginkgo
biloba is used in Chinese medicine to treat asthma and
coughing. While the chemical and biological properties
of individual EGb761 component have been investigated
in vitro and in vivo [37-39], the standardized extract
EGb761 is often used in clinical research [40]. A
Cochrane systematic review did not support the use of
EGb761 in dementia treatment [40]. Another report also
suggested that EGb761 was not effective in reducing the
incidence of AD [41]. Although clinical efficacy of
EGb761 for dementia treatment is still controversial, the
use of a well-defined herbal extract in clinical studies
has been demonstrated.
Chinese medicine theories and anti-dementia drug
research Chinese medicine theory and western pharma-
cology may be integrated for the development of anti-
dementia Chinese herbal extracts. According to Chinese
medicine theory, the fruit of L. barbarum (Gouqizi),
which is used to tonify the Yin in our body, nourishes
our Eye (Yan), Liver (Gan) and Kidney (Shen); its anti-
aging effects are well-documented in Chinese medicine
literature [42]. In our laboratory, research of standar-
dized L. barbarum extract is based on Chinese medicine
concepts. Firstly, L. barbarum is chosen as the research
candidate because of its unique Chinese medicine prop-
erties. Secondly, the research direction of our standar-
dized L. barbarum extract was inspired by Chinese
medicine theory. Owing to anti-aging properties, L. bar-
barum may alleviate aging-associated neurodegenerative
diseases such as AD and VaD [9]. Quality control of our
raw materials ensured the quality of our L. barbarum
extract [43]. We found that L. barbarum extract attenu-
ated Ab peptide induced neuronal apoptosis [43]. The
holistic concept in Chinese medicine inspired us to
study the effects of the extract on other dementia
related pathological and risk factors. We then discovered
that L. barbarum extract protected neurons against glu-
tamate toxicity, suggesting that it might slow down
dementia progression [44]. We also demonstrated that
L. barbarum extract protected neurons against homo-
cysteine toxicity where hyperhomocysteinaemia is a risk
factor for AD [45].
Herbal formulations
Yokukansan Yokukansan, or TJ-54, is a Kampo herbal
remedy originating from the Chinese herbal formula
Yigan San developed in the Song Dynasty for the treat-
ment of Liver (Gan) dysfunction-induced agitation and
restlessness in children. Yigan San consists of seven
herbs, namely Angelica acutiloba (Danggui), Atracty-
lodes lancea (Baishu), Bupleurum falcatum (Chaihu),
Poria cocos (Fuling), Cnidium officinale (Chuanxiong),
Uncaria rhynchophylla (Gouteng) and Glycyrrhiza ura-
lensis (Gancao) at a ratio of 3:4:2:4:3:3:1.5. This compo-
sition is also used in Yokukansan [46]. Since this
remedy is used for the treatment of psychiatric disorder,
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the possible therapeutic effects on dementia symptoms
are under investigation.
Both clinical and preclinical studies on Yokukansan
support its use in dementia treatment. A randomized,
observer-blind, controlled trial found that a 4-week
Yigan San treatment improved the behavioral and psy-
chological symptoms of dementia (BPSD) [47] which
includes aggression, agitation, screaming, wandering,
hallucinations and delusions. These symptoms develop
in 20-80% of dementia patients at different stages [48].
Yigan San reduced cholinesterase inhibitor-resistant
visual hallucination in a small group of patients of
dementia with Lewy bodies [49]. Positive effects of
Yokukansan on sleep disturbance in dementia patients
were also reported [50]. A randomized cross-over study
(subjects receiving active treatment or placebo in differ-
ent stages of the trial) found that Yokukansan signifi-
cantly improved the BPSD in AD patients but had no
effects on their cognitive functions as demonstrated by
the MMSE score. Effects of Yokukansan could persist
for one month and was well-tolerated [51]. Other stu-
dies also found that Yokukansan was safe and effective
in treating BPSD in AD and even PD patients [52,53].
Yokukansan might modulate the glutamatergic neuro-
transmitter system; hence protecting neurons against
excitotoxicity [54,55]. Yokukansan provided direct pro-
tection on neurons or through modulating the gluta-
mate reuptake by astrocytes [56]. Yokukansan also
affected the expression of serotonin receptor in the
frontal cortex of mice injected with 2,5-dimethoxy-4-
iodoamphetamine [57].
Challenges in developing anti-dementia herbal for-
mulations Apart from Yigan San, some other Chinese
herbal formulae are effective in treating the dementia
[58,59]. Most of these studies are single clinical trials
performed on a single formula. There are few studies
on action mechanisms. Moreover, few studies use Chi-
nese medicine diagnostic criteria. In other words, the
effects of a definite formula were tested on patients
regardless of their dementia subtype in Chinese medi-
cine diagnosis. As exemplified in a clinical trial for
respiratory diseases, it should be feasible to incorporate
Chinese medicine diagnosis in the clinical trials for
dementia [60].
Conclusion
While Chinese herbal medicine is considered a big che-
mical library, potential drugs of single molecules have
been developed for the treatment of AD and VaD but
Chinese medicine concepts have not been fully incorpo-
rated for new drug development in Chinese medicine.
As Chinese medicine aims to restore harmony of the
whole body rather than only target the brain in treating
encephalopathy [61], further research into experimental
and clinical sciences should be conducted to explain
how Chinese medicine can treat and prevent AD and
VaD.
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